Exhibit 10.1.40 OPTION AGREEMENT THIS AGREEMENT entered into this 1st day of February 2000 between Neoprobe Corporation, a Delaware corporation with principal offices at 425 Metro Place North, Suite 300, Dublin, Ohio 43017-1331 (hereinafter...Option Agreement • May 15th, 2000 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
EXHIBIT 10.4 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, supplemented, restated or otherwise modified from time to time, the "SECURITY AGREEMENT"), dated as of December 13, 2004, made by Neoprobe Corporation, a Delaware corporation...Security Agreement • December 16th, 2004 • Neoprobe Corp • Surgical & medical instruments & apparatus • New York
STOCK PURCHASE AGREEMENT BY AND AMONG DAN MANOR, ELI LEVI, RONI BIBI, FIRST ISRATECH FUND LP, FIRST ISRATECH FUND LLC, FIRST ISRATECH FUND NORWAY A.S. GREATWAY COMMERCIAL INC., UZI ZUCKER, CAREMI PARTNERS, EMICAR, LLC, AND MA'ARAGIM ENTERPRISES LTD....Stock Purchase Agreement • January 8th, 2002 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Delaware
RECITALS:Termination Agreement • November 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances
Change of Annual Control Name Base Salary Severance Severance --------------- ----------- --------- --------- Rodger A. Brown $ 115,000 $ 115,000 $ 230,000 Brent L. Larson $ 135,000 $ 135,000 $ 270,000Employment Agreement • March 30th, 2004 • Neoprobe Corp • Surgical & medical instruments & apparatus • Ohio
NAVIDEA BIOPHARMACEUTICALS, INC. 8,000,000 Common Stock (par value $.001 per share) Underwriting AgreementUnderwriting Agreement • June 17th, 2019 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
Navidea Biopharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,000,000 shares of its common stock, par value $.001 per share (the “Shares”). The 8,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,200,000 Shares as provided in Section 2. The additional 1,200,000 Shares that may be sold by the Company pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“Wainwright”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares
EV PRODUCTSSupply Agreement • June 3rd, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Pennsylvania
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG NEOPROBE CORPORATION BIOMEDICAL VALUE FUND, L.P. BIOMEDICAL OFFSHORE VALUE FUND, LTD.Securities Purchase Agreement • December 16th, 2004 • Neoprobe Corp • Surgical & medical instruments & apparatus • Delaware
April 2, 2003Security Agreement • April 9th, 2003 • Neoprobe Corp • Surgical & medical instruments & apparatus • Ohio
PREAMBLE:Separation Agreement • April 12th, 1999 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
RECITALSShareholder Agreement • January 8th, 2002 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement is made and entered into effective as of January 1, 2005 (the "Effective Date"), by and between NEOPROBE CORPORATION, a Delaware Corporation with a place of business at 425 Metro Place North,...Employment Agreement • January 5th, 2005 • Neoprobe Corp • Surgical & medical instruments & apparatus • Ohio
EXHIBIT 10.4.23 --------------- LOAN AGREEMENT -------------- This agreement is made effective April 16, 1998, between Neoprobe Corporation, a Delaware corporation ("Borrower"), and Bank One, NA, a national banking association ("Lender"). Background...Loan Agreement • August 14th, 1998 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
WARRANT TO PURCHASE COMMON STOCK OF NEOPROBE CORPORATIONNeoprobe Corp • April 9th, 2003 • Surgical & medical instruments & apparatus • Ohio
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 4th, 2006 • Neoprobe Corp • Surgical & medical instruments & apparatus • Illinois
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 1, 2006, by and between NEOPROBE CORPORATION, a Delaware corporation, (the "Company"), and FUSION CAPITAL FUND II, LLC (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 12th, 2010 • Neoprobe Corp • Surgical & medical instruments & apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 7, 2010, among Neoprobe Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WHEREAS:Registration Rights Agreement • April 9th, 2003 • Neoprobe Corp • Surgical & medical instruments & apparatus • Delaware
PREAMBLERestricted Stock Purchase Agreement • March 31st, 1997 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
WARRANT TO PURCHASE COMMON STOCK OF NEOPROBE CORPORATIONNeoprobe Corp • March 30th, 2004 • Surgical & medical instruments & apparatus • Ohio
WARRANT AGENCY AGREEMENTWarrant Agency Agreement • August 2nd, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
WARRANT AGENCY AGREEMENT, dated as of August [ ], 2022 (“Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
RECITALSStock Purchase Agreement • December 2nd, 2003 • Neoprobe Corp • Surgical & medical instruments & apparatus • New York
SERIES DD COMMON STOCK PURCHASE WARRANT NEOPROBE CORPORATIONNeoprobe Corp • November 12th, 2010 • Surgical & medical instruments & apparatus
THIS SERIES DD COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the two (2) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Neoprobe Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
RECITALS:Security Agreement • March 30th, 2000 • Neoprobe Corp • In vitro & in vivo diagnostic substances
Series S No. S-001 THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE OTHER SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED...Neoprobe Corp • December 2nd, 2003 • Surgical & medical instruments & apparatus • Delaware
EXHIBIT 10.34 THE WARRANTS REPRESENTED BY THIS CERTIFICATE AND THE OTHER SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE...Warrant Agreement • December 2nd, 2003 • Neoprobe Corp • Surgical & medical instruments & apparatus • Delaware
CONFIDENTIALNeoprobe Corp • November 12th, 2010 • Surgical & medical instruments & apparatus • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 7th, 2014 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 4, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and NAVIDEA BIOPHARMACEUTICALS, INC., a Delaware corporation with offices located at 5600 Blazer Parkway, Dublin, OH 43017 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
EXHIBIT 10.4.25 SECURITY AGREEMENT ------------------ This agreement is made April 16, 1998, at Columbus, Ohio, between Neoprobe Corporation, a Delaware corporation ("Debtor"), whose address is 425 Metro Place South, Suite 400, Dublin, Ohio...Security Agreement • August 14th, 1998 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • December 4th, 2006 • Neoprobe Corp • Surgical & medical instruments & apparatus • Illinois
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of December 1, 2006, by and between NEOPROBE CORPORATION, a Delaware corporation (the “Company”), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
Exhibit 10.3 AMENDMENT 2 TO THE RIGHTS AGREEMENT This Amendment 2 ("Amendment") to the Rights Agreement ("Agreement") between Neoprobe Corporation, a Delaware corporation ("Company"), and Continental Stock Transfer & Trust Company ("Rights Agent") is...The Rights Agreement • March 31st, 2005 • Neoprobe Corp • Surgical & medical instruments & apparatus
1 EXHIBIT 10.4.31 ASSET PURCHASE AGREEMENT THIS AGREEMENT is made by and between NEOPROBE EUROPE AKTIEBOLAG, reg. no 556440-1510, a corporation organized and existing under the laws of Sweden, whose registered office is at Solvegatan 41, SE-223 70...Asset Purchase Agreement • November 16th, 1998 • Neoprobe Corp • In vitro & in vivo diagnostic substances
WHEREAS:Registration Rights Agreement • December 2nd, 2003 • Neoprobe Corp • Surgical & medical instruments & apparatus • New York
ARTICLE I DEFINITIONSShare Purchase Agreement • May 15th, 2000 • Neoprobe Corp • In vitro & in vivo diagnostic substances
EXHIBIT 10.3.47 LICENSE & OPTION AGREEMENT THIS AGREEMENT entered into this 1st day of April, 1998, between Neoprobe Corporation, a Delaware corporation with principal offices at 425 Metro Place North, Suite 300, Dublin, Ohio 43017-1367 (hereinafter...Option Agreement • August 14th, 1998 • Neoprobe Corp • In vitro & in vivo diagnostic substances • Ohio
NAVIDEA BIOPHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENTDealer-Manager Agreement • August 2nd, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
The following will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”) and to holders of the outstanding warrants issued to the underwriter in our public offering in 2019, Series D Preferred Stock, and Series F Preferred Stock (the “Participating Securities”), subscription rights (the “Rights”) to subscribe for up to an aggregate of 35,000 units (the “Units”), each Unit consisting of one share of Series I Convertible Preferred Stock, par value $0.001 per share (the “Rights Shares”) and one warrant, with each warrant representing the right to purchase 1,538 shares of Common Stock (the “Rights Warrants” and the Rights Shares, the Rights Warrants and the shares of Common Stock issuable upon conversion of the Rights Shares and ex
